Valuation: Amicus Therapeutics, Inc.

Market Cap 454.99Cr 392.97Cr 369.74Cr 336.04Cr 632.04Cr 44TCr 641.3Cr 4.34TCr 1.7TCr 22TCr 1.71TCr 1.67TCr 73TCr P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 469.87Cr 405.83Cr 381.83Cr 347.03Cr 652.71Cr 45TCr 662.28Cr 4.48TCr 1.76TCr 23TCr 1.76TCr 1.73TCr 75TCr EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+1.05%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.28
Extreme 7.285
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
20/01/26 Fiscal year

Chief Executive Officer

2,25,000 0.0727%
02/01/26 Tax

General Counsel

43,109 0.0139%
02/01/26 Tax

Executive/Senior Manager

30,007 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+95.55%+13.11% 454.99Cr
+1.59%+1.24%+2.32%+21.98% 4.86TCr
+1.89%+5.08%+492.59%+629.24% 4.63TCr
+1.83%+2.75%+15.61%+91.22% 4.2TCr
-0.50%-1.56%+24.67%+12.17% 3.95TCr
-2.74%-7.13%+18.72%+49.04% 3.17TCr
-1.14%-2.51%+27.52%+136.42% 1.65TCr
+0.59%-2.25% - - 1.63TCr
+0.32%+0.40%+3.07%+29.99% 1.4TCr
-2.60%-1.00%+77.85%+40.37% 1.33TCr
Average -0.50%-0.84%+84.21%+113.73% 2.73TCr
Weighted average by Cap. -0.37%-0.42%+105.69%+153.34%

Financials

2024 2025
Net sales 53Cr 46Cr 43Cr 39Cr 73Cr 5.06TCr 74Cr 503.59Cr 197.36Cr 2.53TCr 198.35Cr 194.04Cr 8.43TCr 63Cr 55Cr 52Cr 47Cr 88Cr 6.08TCr 89Cr 604.55Cr 236.92Cr 3.04TCr 238.11Cr 232.95Cr 10TCr
Net income -5.61Cr -4.85Cr -4.56Cr -4.14Cr -7.79Cr -537.57Cr -7.91Cr -53Cr -21Cr -268.86Cr -21Cr -21Cr -895.55Cr -2.71Cr -2.34Cr -2.2Cr -2Cr -3.77Cr -259.75Cr -3.82Cr -26Cr -10Cr -129.91Cr -10Cr -9.96Cr -432.72Cr
Net Debt 19Cr 17Cr 16Cr 14Cr 27Cr 1.86TCr 27Cr 184.64Cr 72Cr 928.21Cr 73Cr 71Cr 3.09TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 141.87Cr 56Cr 713.18Cr 56Cr 55Cr 2.38TCr
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock